Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial

NCT07297654 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT07297654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
May 31, 2028
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma